Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Pfizer Inc. is conducting a Phase 3 clinical study titled ‘A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents ≥ 6 to <18 Years of Age.' The study aims to assess the efficacy and safety of rimegepant compared to a placebo for preventing migraines in young patients. This research is significant as it targets a younger demographic suffering from episodic migraines, potentially offering a new preventative treatment option.
The intervention being tested is Rimegepant, an oral dissolvable tablet (ODT) available in 75mg or 50mg doses. It is designed to prevent migraines by acting as an active comparator against a matching placebo.
The study follows an interventional design with random allocation and a sequential intervention model. It employs quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are all blinded to the treatment assignments. The primary purpose of the study is prevention.
The study began on February 28, 2022, and is currently recruiting participants. The last update was submitted on June 23, 2025. These dates are crucial as they indicate the study’s progression and the timeline for potential results.
For investors, this study could impact Pfizer’s stock performance positively if the results demonstrate significant efficacy and safety, potentially leading to a new market for pediatric migraine prevention. Competitors in the pharmaceutical industry may also be influenced as they assess their own pipelines in response to Pfizer’s developments.
The study is ongoing, and further details are available on the ClinicalTrials portal.